Hi-Tech Pharmacal launches topical pain treatment
AMITYVILLE, N.Y. — The Food and Drug Administration has approved a topical pain treatment made by Hi-Tech Pharmacal, the drug maker said Thursday.
The agency approved Hi-Tech’s sterile lidocaine jelly in the 2% strength, used for treating pain in procedures involving the urethra, painful urethritis and in endotracheal intubation.
Various versions of the drug had sales of $17 million in 2010, according to IMS Health.
Actavis’ generic Valtrex OKed by FDA
MORRISTOWN, N.J. — The Food and Drug Administration has approved a generic treatment for shingles and genital herpes made by Actavis, the drug maker said Wednesday.
The FDA approved Actavis’ valacyclovir hydrochloride tablets in the 500-mg and 1-g strengths.
The drug is a generic version of GlaxoSmithKline’s Valtrex. Branded and generic forms of the drug had sales of about $1.5 billion in 2010, according to IMS Health.
Mylan to launch educational site about generic drugs
PITTSBURGH — Though more than 7-in-10 drugs dispensed in the United States today are generics, and the Food and Drug Administration holds generics to the same standards as branded drugs, misgivings among the general public still exist, fed by the occasional media report of patients experiencing bad side effects after taking certain generic drugs.
In response, generic drug maker Mylan has launched an educational site about generic drugs, ChoosingGenerics.com. The website will include facts about generics, information about savings that patients can get from generics and ways for patients to talk to their doctors and pharmacists.
“While the debate over healthcare reform continues, one of the only proven solutions for controlling the rise of healthcare costs is generic pharmaceuticals,” Mylan president Heather Bresch said. “Generic drug companies have been providing high-quality, FDA-approved affordable alternatives to expensive branded medications in the [United States] for more than 25 years.”